BidaskClub Lowers Vertex Pharmaceuticals (VRTX) to Sell
BidaskClub downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from a hold rating to a sell rating in a research report report published on Thursday, September 20th.
Several other analysts also recently commented on VRTX. Zacks Investment Research upgraded Vertex Pharmaceuticals from a hold rating to a buy rating and set a $178.00 target price on the stock in a research note on Saturday, June 30th. ValuEngine upgraded Vertex Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, June 2nd. BMO Capital Markets raised their price target on Vertex Pharmaceuticals to $204.00 and gave the stock an outperform rating in a research note on Thursday, July 26th. JPMorgan Chase & Co. restated a buy rating on shares of Vertex Pharmaceuticals in a research note on Sunday, July 1st. Finally, Argus set a $172.00 price target on Vertex Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, June 12th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. Vertex Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $197.68.
Shares of Vertex Pharmaceuticals stock traded up $5.66 during midday trading on Thursday, hitting $181.32. The company had a trading volume of 1,198,957 shares, compared to its average volume of 1,528,475. The company has a quick ratio of 3.55, a current ratio of 3.67 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $49.26 billion, a P/E ratio of 226.65, a PEG ratio of 1.96 and a beta of 1.48. Vertex Pharmaceuticals has a 52-week low of $136.50 and a 52-week high of $194.92.
In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 2,098 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $174.44, for a total transaction of $365,975.12. Following the completion of the transaction, the senior vice president now owns 17,376 shares in the company, valued at $3,031,069.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Reshma Kewalramani sold 2,305 shares of the business’s stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $186.95, for a total value of $430,919.75. Following the transaction, the chief marketing officer now owns 1,909 shares of the company’s stock, valued at approximately $356,887.55. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,560 shares of company stock valued at $7,436,746. 0.75% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the business. Mount Yale Investment Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $101,000. Kaizen Advisory LLC raised its stake in shares of Vertex Pharmaceuticals by 147.3% during the second quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock valued at $102,000 after acquiring an additional 358 shares in the last quarter. Sun Life Financial INC raised its stake in shares of Vertex Pharmaceuticals by 266.1% during the second quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock valued at $118,000 after acquiring an additional 503 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $125,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Vertex Pharmaceuticals by 3,126.1% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock valued at $126,000 after acquiring an additional 719 shares in the last quarter. Institutional investors and hedge funds own 93.47% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Featured Story: Buyback
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.